This is the second article in a series. January 13, 2015—A new session of Congress has begun with two longtime champions of the 340B program in retirement and a new majority party in the Senate. … [Read more...]
What’s In Store for 340B in 2015 (Part 1)
Pricing transparency and calls to reopen the 340B statuteNote: This article is the first in a series. January 8, 2015—A little over nine years ago, Congress wanted to know why health care providers had no way to tell whether they were being overcharged for 340B discounted drugs. … [Read more...]
HRSA Clarifies 340B Duplicate Discount Policy
Says exclusion file does not pertain to Medicaid managed careDecember 16, 2014—The database that the Health Resources and Services Administration maintains to protect drugmakers from paying both 340B discounts and Medicaid rebates on the same drugs applies only to Medicaid fee-for-service and not to Medicaid managed care claims, HRSA clarified yesterday in an updated 340B policy release. … [Read more...]
The Top Ten 340B Stories of 2014
Regulations were our readers' leading preoccupationDecember 16, 2014—For the 340B community, 2014 will go down as the year that a federal court invalidated the 340B orphan drug exclusion regulation, derailing the long-awaited 340B "mega-reg" plus other program regulations in the works. … [Read more...]
Spending Bill’s Report Contains 340B Directives
Appropriators address ceiling price availability, patients' access to savingsDecember 10, 2014—House and Senate appropriators agreed yesterday on a $1.1 trillion fiscal 2015 federal spending bill with report language about the 340B program. Congress has yet to vote on the measure. … [Read more...]
340B Addressed During House Hearing on Health Spending
Health panel's chair asks if it's time to re-evaluate programDecember 10, 2014—The chairman of the House Energy & Commerce Health Subcommittee asked during a hearing yesterday whether the 340B program should be re-evaluated. … [Read more...]
How is the Drug Industry Doing These Days?
The drug industry and its surrogates love to repeat the ridiculous line that the 340B drug discount program "is being exploited by rich hospitals to boost their bottom lines." Drug companies, they claim, are "incurring heavy losses from 340B abuse," as one drug company apologist recently put it. SNHPA has created an infographic that sets the record straight. It compares the … [Read more...]